Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Tumor-specific Cytotoxic Activity of 1,2,3,4-Tetrahydroisoquinoline Derivatives against Human Oral Squamous Cell Carcinoma Cell Lines

HAJIME HATANO, FUMIHIRO TAKEKAWA, KEN HASHIMOTO, MARIKO ISHIHARA, MASAMI KAWASE, CHU QING, WANG QIN-TAO and HIROSHI SAKAGAMI
Anticancer Research August 2009, 29 (8) 3079-3086;
HAJIME HATANO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
FUMIHIRO TAKEKAWA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KEN HASHIMOTO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MARIKO ISHIHARA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MASAMI KAWASE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CHU QING
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
WANG QIN-TAO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIROSHI SAKAGAMI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: sakagami{at}dent.meikai.ac.jp
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

The tumor-specific cytotoxicity and the type of cell death induced by thirty-eight newly synthesized tetrahydroisoquinoline derivatives in human oral squamous cell carcinoma cell lines were investigated. 6,7-Dimethoxy-3,4-dihydroisoquinolin-2(1H)-yl)(3,4-dimethoxyphenyl) methanone that has bulky substituents (such as 3,4-dimethoxybenzoyl group) (TQ9) and ethyl 2-benzyloxycarbonyl-1,2,3,4-tetrahydroisoquinoline-1-carboxylate that has ethoxycarbonyl group and benzyloxycarbonyl group (TD13) showed the highest tumor-specific cytotoxicity (TS=12.5 and 5.3, respectively). This supports the importance of molecular size for the cytotoxicity induction. TQ9 induced internulceosomal DNA fragmentation and caspase-3 activation only marginally in HL-60 cells, whereas it enhanced the formation of acidic organelles (stained with acridine orange) without induction of DNA fragmentation or caspase-3 activation in human squamous cell carcinoma cell lines (HSC-2, HSC-4), suggesting the induction of autophagy in the latter cells.

  • Tetrahydroisoquinolines
  • tumor-specificity
  • cytotoxicity
  • autophagy

1-Methyl-1,2,3,4-tetrahydroisoquinoline is the only endogenous Parkinsonism-preventing agent discovered to date (reviewed in (1)). The incorporation of the 1,2,3,4-tetrahydroisoquinoline (TIQ) moiety is an important synthetic strategy in drug discovery (2). The high therapeutic properties of the related drugs have encouraged medicinal chemists to synthesize a large number of novel chemotherapeutic agents. Pharmaceutical properties including antineoplastic (3, 4), nitric oxide (NO) inhibitory (5), histamine H3 antagonist and serotonin reuptake inhibitory (6), α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor antagonistic (7), bradycardic (8), orexin-2 receptor-selective antagonistic (9), multidrug resistance (MDR) reversal (10-12), γ-secretase inhibitory (13), kinase insert domain-containing receptor (KDR) inhibitory (14), and antidiabetic activities (15), are all unique characteristics known for newly synthesized TIQ derivatives. On the other hand, the TIQ family of alkaloids also includes potent cytotoxic agents that display a range of biological properties such as antitumor and antimicrobial activities (16).

There is real perceived need for the discovery of new compounds endowed with antitumor activity, possibly acting through mechanisms of action which are distinct from those of well-known classes of antitumor agents. Through the various molecules designed and synthesized for this aim, it was demonstrated that N-acyl-TIQ derivatives could be considered as future anticancer candidates. As a part of our exhaustive search for the substances that show selective cytotoxicity against human oral squamous cell carcinoma (OSCC) cell lines, we investigated the tumor-specific cytotoxicity and the type of cell death induced in OSCC cells by thirty-eight newly synthesized TIQ derivatives, TQ1-19 (Figure 1A) and TD1-19 (Figure 1B) (Table I).

Materials and Methods

Materials. The following chemicals and reagents were obtained from the indicated companies: Dulbecco's modified Eagle's medium (DMEM) (GIBCO BRL, Grand Island, NY, USA); RPMI-1640 medium, fetal bovine serum (FBS), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), acridine orange (Sigma-Aldrich Inc., St. Louis, MO, USA); dimethyl sulfoxide (DMSO) (Wako Pure Chem. Ind., Osaka, Japan).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

The structure of 1,2,3,4-tetrahydroisoquinoline derivatives. (A) TQ1-19, (B) TD1-19.

Preparation of 1,2,3,4-tetrahydroisoquinoline (TIQ) derivatives. Thirty-eight 1,2,3,4-tetrahydroisoquinoline derivatives (TQ1-19 and TD1-19) (Table I) were prepared as described elsewhere (17-30).

Cell culture. Three human oral tumor cell lines (HSC-2, HSC-3, HSC-4) and three human normal cell types (HGF, HPC, HPLF) were cultured in DMEM supplemented with 10% heat-inactivated FBS. Human promyelocytic leukemic HL-60 cells were cultured in RPMI-1640 supplemented with 10% heat-inactivated FBS. Tumor cell lines were obtained from Riken Cell Bank. Normal cells were prepared from periodontal tissues according to the guideline of the Institutional Board of Meikai University Ethics Committee (Number A0808) with informed consent from the patients. Since HGF, HPC and HPLF cells have a limited lifespan due to in vitro senescence (31), these cells were used at the population doubling level of 7-11 for the present study.

Assay for cytotoxic activity. Cells (except for HL-60 cells) were inoculated at 3×103 cells/0.1 ml in 96-microwell plates (Becton Dickinson Labware, NJ, USA), unless otherwise stated. After 48 hours, the medium was removed by suction with an aspirator, and replaced with 0.1 ml of fresh medium containing different concentrations of test compounds. The first well contained a 400 μM sample and was diluted 2-fold sequentially, with triplicate wells for each concentration. Cells were incubated for another 48 hours, and the relative viable cell number was then determined by MTT method. In brief, cells were replenished with fresh culture medium containing 0.2 mg/ml MTT and incubated for another 4 hours. The cells were lysed with 0.1 ml of DMSO, and the absorbance at 540 nm of the cell lysate was determined using a microplate reader (Biochromatic Labsystem, Helsinki, Finland) (32). A540 of control cells was usually in the range from 0.50 to 1.2.

HL-60 cells were inoculated at 5×104/0.1 ml in 96-microwell plates and test compounds were added. After incubation for 48 hours, the viable cell number was determined by trypan blue exclusion, under a light microscope.

The 50% cytotoxic concentration (CC50) was determined from the dose-response curve. Tumor-specificity (TS) was determined by the following equation: TS={[CC50 (HGF) + CC50 (HPC) + CC50 (HPLF)] / [CC50 (HSC-2) + CC50 (HSC-3) + CC50 (HSC-4) + CC50 (HL-60)]} x (4/3).

Assay for DNA fragmentation. HSC-2 or HSC-4 cells (9×104) were inoculated onto 6-well plates (9.6 cm2) and left for 48 hours to allow their complete adherence to the plate. Adherent HSC-2, HSC-4 cells or HL-60 cells freshly prepared (5×105) were cultured for 6 or 24 hours in fresh culture medium (3 ml) without (control) or with the indicated concentrations of samples. Cells were then harvested, washed once with phosphate-buffered saline without calcium and magnesium (PBS(-)) and lysed with 50 μl lysis buffer [50 mM Tris-HCl (pH 7.8), 10 mM EDTA-2Na, 0.5% (w/v) sodium N-laurylsarcosinate solution]. The lysate was incubated with 0.4 mg/ml RNase A and 0.8 mg/ml proteinase K for 1-2 hours at 50°C, and then mixed with 50 μl NaI solution (7.6 M NaI, 20 mM EDTA-2Na, 40 mM Tris-HCl, pH 8.0) and 200 μl of ethanol. After centrifugation for 20 minutes at 20,000×g, the precipitate was washed with 1 ml of 70% ethanol and dissolved in TE buffer (10 mM Tris-HCl, 1 mM EDTA-2Na, pH 8.0). A sample (10-20 μl) was applied to 2% agarose gel electrophoresis in TBE buffer (89 mM Tris-HCl, 89 mM boric acid, 2 mM EDTA-2Na, pH 8.0). DNA molecular marker (Bayou Biolabs, Harahan, LA, USA) and DNA from apoptotic HL-60 cells induced by UV irradiation (33) were run in parallel. After staining with ethidium bromide, DNA was visualized by UV irradiation, and photographed by CCD camera (Bio Doc-It, UVP, Inc., Upland, CA, USA).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Preparation of thirty-eight 1,2,3,4-tetrahydroisoquinoline derivatives.

Assay for caspase activation. HSC-2 or HSC-4 cells (6×105) were inoculated on 8.5 cm plates and incubated for 48 hours to allow their complete adherence. The adherent HSC-2 or HSC-4 cells, and HL-60 cells freshly prepared (3×106 in 6-well plates) were further incubated for 6 hours in fresh medium without (control) or with the test samples. Cells were washed with PBS(-) and lysed in lysis solution [50 mM Tris-HCl (pH 7.5), 0.3% NP-40, 1 mM DTT]. After standing for 10 minutes on ice and centrifugation for 5 minutes at 21,000×g, the supernatant was collected. Lysate (50 μl, equivalent to 200 μg protein) was mixed with 50 μl lysis solution containing substrates for caspase-3 (DEVD-pNA (p-nitroanilide)). After incubation for 18 hours at 37°C, the absorbance at 405 nm of the liberated chromophore pNA was measured by a microplate reader (32).

Detection of acidic vesicular organelles with acridine orange staining. Acidic vesicular organelles were imaged by staining the cells with 0.1 μg/ml acridine orange for 20 minutes. Samples were then examined under Laser Scanning Microscope LSM510 (Carl Zeiss Inc., Gottingen, Germany) using the following filters: excitation filter 488 nm, emission filter 505-530 nm and >650 nm (32).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Cytotoxicity of 1,2,3,4-tetrahydroisoquinoline derivatives (TQ compounds) on human tumor and normal cells.

Statistical analysis. Significance of the difference of control and treated-samples was evaluated by Student's t-test.

Results

Cyotoxicity and tumor-specificity. We first investigated the cytotoxicity of nineteen TQ compounds (TQ1-TQ19) (Figure 1A, Table II). Among 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolines (TQ1-3, TQ8-10), the substituents at the C-2 position (R3) seem to be important. TQ9 with a 3,4-dimethoxybenzoyl group showed the highest tumor-specific cytotoxicity (TS=12.5). Introduction of -CH2OH (TQ5), trifluoroacetyl group (TQ11, TQ12, TQ13), -CH(OCOC6H4-4-Cl)CF3 (TQ15), -CH(OCOC6H4-4-OMe)CF3 (TQ16) or -CH(OCOBut)CF3 group (TQ17) at the C-1 position (R2) gave intermediate tumor-specificity indices (TS=>2.0, 3.4, >2.8, 2.6, 1.9, 3.0, and 2.0, respectively).

We next investigated the cytotoxicity of nineteen TD compounds (TD1-TD19) (Figure 1B, Table III). All nine compounds (TD1-9) that have a -COOH group at C-1 (R2) showed much lower cytotoxicity and tumor-specificity (TS=1.0-1.3). On the other hand, TD11 with a -CH2COOH group (R2), and TD13 and TD15 with a -COOCH2 CH3 group at C1 (R2) showed higher TS values (TS= >2.6, 5.2 and 2.1, respectively).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table III.

Cytotoxicity of 1,2,3,4-tetrahydroisoquinoline derivatives (TD compounds) on human tumor and normal cells.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Induction of DNA fragmentation by two 2-aminotropolone derivatives. Near confluent HL-60 (A, B) or HSC-2, HSC-4 cells (C) were incubated for 6 or 24 hours with the indicated concentrations of TQ9 (A, C) or TD13 (B). DNA was then extracted and applied to agarose gel electrophoresis. M: Marker DNA. UV, DNA from the HL-60 cells exposed to 1-min UV irradiation (32).

Induction of apoptosis. Untreated control HL-60 cells spontaneously produced an internucleosomal DNA fragmentation pattern, suggesting relatively higher susceptibility of this cell line to apoptosis inducers. TQ9 and TD13 (10-40 μM) slightly enhanced the DNA fragmentation in HL-60 cells, but to a much lesser extent than that attained by UV irradiation (Figure 2A, B). TQ9 failed to induce internucleosomal DNA fragmentation in HSC-2 and HSC-4 cells (Figure 2C).

Figure 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3.

Effect of TQ9 on caspase-3 activity. Near confluent HSC-2, HC-4 and HL-60 cells were incubated for 6 hours with the indicated concentrations of TQ9, or exposed to 1 min UV irradiation followed by 6 hours inculation (32). Each point represents the mean±S.D. from triplicate assays. Significance between control and treated cells: *p=0.046, **p=0.137.

TQ9 (20 μM) activated caspase-3 (p<0.05) in HL-60 cells, but to much lesser extent than that achieved by UV irradiation (Figure 3). TQ9 failed to activate the caspase-3 in both HSC-2 and HSC-4 cells (Figure 3). It is notable that UV irradiation activated caspase-3 to a much lesser extent in HSC-2 cells as compared to HL-60 cells, whereas it did not activate caspase-3 at all in HSC-4 cells (Figure 3).

Induction of autophagy. We next investigated whether TQ9 induces autophagy in HSC-2 and HSC-4 cell lines. When these cells were incubated for 1 hour in Hank's balanced solution, acidic organelles (stained by acridine orange) became apparent (Figure 4D, H), confirming a previous report (34). Treatment of HSC-2 cells for 6 hours with TQ9 (40, 80 μM) enhanced the production of acidic organelles (Figure 4B, C), as compared with control cells (Figure 4A). Untreated HSC-4 cells produced higher amounts of acidic organelles (Figure 4E). Treatment of HSC-4 cells for 6 hours with TQ9 (120 μM) slightly enhanced the production of acidic organelles (Figure 4G). These data suggest that TQ9 may induce autophagy in HSC-2 and HSC-4 cells.

Figure 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 4.

Induction of the production of acidic organelles by TQ9. HSC-2 (A-D) and HSC-4 cells (E-H) were incubated for 6 hours without (A, E) or with 40 (B), 60 (F), 80 (C), or 120 (G) μM TQ9 in DMEM+10% FBS, or for 1 hour in Hank's balanced salt solution (D, H). The cells were stained with acridine orange for the detection of acidic organelles.

Discussion

The present study demonstrated that TIQ compounds with bulky substituents such as a 3,4-dimethoxybenzoyl group at C-2 (R3) (TQ9), and an ethoxycarbonyl group at C-1 (R2) and benzyloxycarbonyl group at C-2 (R3) (TD13) showed the highest cytotoxicity and tumor-specificity (TS=12.5 and 5.3, respectively). This finding confirms a previous report that TIQ derivatives possessing bulky alkyl group substituents such as 1-cyclobutyl-, 1-cyclohexyl-, 1-phenyl, or 1-benzyl-at the C-1 position significantly showed cytotoxicity against PC12 cells (35). We also recently found a good correlation between the cytotoxicity of TQ compounds and their molecular size (such as surface area, volume and width), but not with other physicochemical descriptors (such as heat of formation, stability of hydration, dipole moment, electron affinity, ionization potential, highest occupied molecular orbital energy, lowest unoccupied molecular orbital energy, absolute hardness, molecular weight) (36).

The present study suggests that TQ9 and TD13 may induce little or no apoptosis in HL-60, HSC-2 and HSC-4 cells (Figure 2), but rather induce autophagy. Since acridine orange staining, however, is not a decisive method of autophagy identification, confirmation with more appropriate markers of autophagy is necessary. TIQ derivatives have been found to induce cell death via the decline of ATP level due to the mitochondria inhibition of complex 1, and the DNA damage (1) and inactivation of Cu,Zn-superoxide dismutase induced (37) by free radical formation. TIQ compounds have been reported to induce apoptosis in human leukemic cells (11), dopaminergic neuroblastoma SH-SY5Y cells (38) and rat PC12 cells (39), but induced autophagy accompanied by the selective destruction of mitochondria in rat glioma cells (40). These data suggest that the type of cell death induced by TIQ derivatives depends on the cells investigated.

TIQ derivatives have well established multidrug resistance reversal activity (10-12) and synergistic effect with adriamycin and cisplatin (11). Since TQ9 showed the highest cytotoxicity and tumor specificity, it remains to be investigated whether TQ9 and popular antitumor agents exert synergistic effects.

Acknowledgements

This study was supported in part by a Grant-in-Aid from the Ministry of Education, Science, Sports and Culture of Japan (Sakagami, No. 19592156; Kawase, No. 20590114).

  • Received April 6, 2009.
  • Revision received June 2, 2009.
  • Accepted June 15, 2009.
  • Copyright© 2009 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

References

  1. ↵
    1. Abe K,
    2. Saitoh T,
    3. Horiguchi Y,
    4. Utsunomiya I,
    5. Taguchi K
    : Review. Synthesis and neurotoxicity of tetrahydroisoquinoline derivatives for studying Parkinson's disease. Biol Pharm Bull 28: 1355-1362, 2005.
    OpenUrlPubMed
  2. ↵
    1. Page D,
    2. Nguyen N,
    3. Bernard S,
    4. Coupal M,
    5. Gosselin M,
    6. Lepage J,
    7. Adam L,
    8. Brown W
    : New scaffolds in the development of mu opioid-receptor ligands. Bioorg Med Chem Lett 13: 1585-1589, 2003.
    OpenUrlPubMed
  3. ↵
    1. Mohler ML,
    2. Kang G-S,
    3. Hong S-S,
    4. Patil R,
    5. Kirichenko OV,
    6. Li W,
    7. Rakov IM,
    8. Geisert EE,
    9. Miller DD
    : Discovery of antiglioma activity of biaryl 1,2,3,4-tetrahydroisoquinoline derivatives and conformationally flexible analogues. J Med Chem 49: 5845-5848, 2006.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Lin H-R,
    2. Safo MK,
    3. Abraham DJ
    : Identification of a series of tetrahydroisoquinoline derivatives as potential therapeutic agents for breast cancer. Bioorg Med Chem Lett 17: 2581-2589, 2007.
    OpenUrlPubMed
  5. ↵
    1. Seo JW,
    2. Srisook E,
    3. Son HJ,
    4. Hwang O,
    5. Cha Y-N,
    6. Chi DY
    : Syntheses of tetrahydroisoquinoline derivatives that inhibit NO production in activated BV-2 microglial cells. Eur J Med Chem 43: 1160-1170, 2008.
    OpenUrlPubMed
  6. ↵
    1. Letavic MA,
    2. Keith JM,
    3. Jablonowski JA,
    4. Stocking EM,
    5. Gomez LA,
    6. Ly KS,
    7. Miller JM,
    8. Barbier AJ,
    9. Bonaventure P,
    10. Boggs JD,
    11. Wilson SJ,
    12. Miller KL,
    13. Lord B,
    14. McAllister HM,
    15. Tognarelli DJ,
    16. Wu J,
    17. Abad MC,
    18. Schubert C,
    19. Lovenberg TW,
    20. Carruther NI
    : Novel tetrahydroisoquinolines are histamine H3 antagonists and serotonin reuptake inhibitors. Bioorg Med Chem Lett 17: 1047-1051, 2007.
    OpenUrlPubMed
  7. ↵
    1. Gitto R,
    2. Ficarra R,
    3. Stancanelli R,
    4. Guardo M,
    5. De Luca L,
    6. Barreca ML,
    7. Pagano B,
    8. Rotondo A,
    9. Bruno G,
    10. Russo E,
    11. De Sarro G,
    12. Chimirri A
    : Synthesis, resolution, stereochemistry, and molecular modeling of (R)- and (S)-2-acetyl-1-(4′-chlorophenyl)-6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline AMPAR antagonists. Bioorg Med Chem 15: 5417-5423, 2007.
    OpenUrlPubMed
  8. ↵
    1. Kubota H,
    2. Watanabe T,
    3. Kakefuda A,
    4. Masuda N,
    5. Wada K,
    6. Ishii N,
    7. Sakamoto S,
    8. Tsukamoto S
    : Synthesis and pharmacological evaluation of piperidinoalkanoyl-1,2,3,4-tetrahydroisoquinoline derivatives as novel specific bradycardic agents. Bioorg Med Chem Lett 14: 3049-3052, 2004.
    OpenUrlPubMed
  9. ↵
    1. Hirose M,
    2. Egashira S,
    3. Goto Y,
    4. Hashihayata T,
    5. Ohtake N,
    6. Iwaasa H,
    7. Hata M,
    8. Fukami T,
    9. Kanatani A,
    10. Yamada K
    : N-Acyl 6,7-dimethoxy-1,2,3,4-tetrahydroisoquinoline: the first orexin-2 receptor selective non-peptidic antagonist. Bioorg Med Chem Lett 13: 4497-4499, 2003.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Fang W,
    2. Li Y,
    3. Cai Y,
    4. Kang K,
    5. Yan F,
    6. Liu G,
    7. Huang W
    : Substituted tetrahydroisoquinoline compounds B3 inhibited P-glycoprotein-mediated multidrug resistance in vitro and in vivo. J Pharm Pharmacol 59: 1649-1655, 2007.
    OpenUrlPubMed
  11. ↵
    1. Yan F,
    2. Jiang Y,
    3. Li Y-M,
    4. Zhen X,
    5. Cen J,
    6. Fang W-R
    : Reversal of P-glycoprotein and multidrug resistance-associated protein 1-mediated multidrug resistance in cancer cells by HZ08 isomers, tetraisohydroquinoline derivatives. Biol Pharm Bull 31: 1258-1264, 2008.
    OpenUrlPubMed
  12. ↵
    1. Li Y,
    2. Zhang H-B,
    3. Huang W-L,
    4. Li Y-M
    : Design and synthesis of tetrahydroisoquinoline derivatives as potential multidrug resistance reversal agents in cancer. Bioorg Med Chem Lett 18: 3652-3655, 2008.
    OpenUrlPubMed
  13. ↵
    1. Hu M-K,
    2. Liao Y-F,
    3. Chen J-F,
    4. Wang B-J,
    5. Tung Y-T,
    6. Lin H-C,
    7. Lee K-P
    : New 1,2,3,4-tetrahydroisoquinoline derivatives as modulators of proteolytic cleavage of amyloid precursor proteins. Bioorg Med Chem 16: 1957-1965, 2008.
    OpenUrlPubMed
  14. ↵
    1. Choquette D,
    2. Teffera Y,
    3. Polverino A,
    4. Harmange J-C
    : Discovery of novel 1,2,3,4-tetrahydroisoquinolines and 3,4-dihydroisoquinoline-1(2H)-ones as potent and selective inhibitors of KDR: synthesis, SAR, and pharmacokinetic properties. Bioorg Med Chem Lett 18: 4054-4058, 2008.
    OpenUrlPubMed
  15. ↵
    1. Azukizawa S,
    2. Kasai M,
    3. Takahashi K,
    4. Mike T,
    5. Kunishiro K,
    6. Kanda M,
    7. Mukai C,
    8. Shirahase H
    : Synthesis and biological evaluation of (S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids: a novel series of PPARγ agonists. Chem Pharm Bull 56: 335-345, 2008.
    OpenUrlPubMed
  16. ↵
    1. Scott JD,
    2. Williams RM
    : Chemistry and biology of the tetrahydroisoquinoline antitumor antibiotics. Chem Rev 102: 1669-1730, 2002.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Ruchirawat S,
    2. Chaisupakitsin M,
    3. Patranuwatana N,
    4. Cashaw JL,
    5. Davis VE
    : A convenient synthesis of simple tetrahydroisoquinolines. Synth Commun 14: 1221-1228, 1984.
    OpenUrl
    1. Stephen S Jr.,
    2. Veradaraj E,
    3. Maurice S
    : Conversion of tetrahydroisoquinolinium salts into benzazepines. J Org Chem 49: 581-586, 1984.
    OpenUrl
    1. Kawase M,
    2. Motohashi N,
    3. Niwa M,
    4. Nozaki M
    : Use of the triflamide group for Friedel-Crafts acylation of N-(β-phenethyl) amino acids to 3-benzazepine derivatives. Heterocycles 45: 1121-1129, 1997.
    OpenUrl
    1. Shah RJ,
    2. Vaghani DD,
    3. Merchant JR
    : Heterocyclic compounds. I. Synthesis of some isoquinoline derivatives. J Org Chem 26: 3533-3534, 1961.
    OpenUrlCrossRef
    1. Kawase M,
    2. Niwa M,
    3. Nozaki M,
    4. Motohashi N
    : Synthesis of 2-trifluoromethyl-2,3,4,5-tetrahydro-1H-3-benzazepine derivatives. Heterocycles 48: 555-560, 1998.
    OpenUrl
    1. Rehse K,
    2. Fredrich D,
    3. Kehr W
    : Neuropsychotropic activity of dopamine-analogous piperidine and piperazine derivatives. Archiv der Pharmazie (Weinheim, Germany) 312: 670-681, 1979.
    OpenUrl
    1. Aissaoui H,
    2. Cappi M,
    3. Clozel M,
    4. Fischli W,
    5. Koberstein R
    : Preparation of 1,2,3,4-tetrahydroisoquinolines as orexin receptor antagonists. PCT Int Appl (2001), 158 pp. CODEN: PIXXD2 WO 2001068609 A1 20010920 CAN 135:257167 AN 2001:693286.
    1. Kawase M,
    2. Okada Y,
    3. Miyamae H
    : The Dakin-West reaction of N-acyl-1,2,3,4-tetrahydroisoquinoline-1-carboxylic acids using trifluoroacetic anhydride: structural revision for the unexpected product. Heterocycles 48: 285-294, 1998.
    OpenUrl
    1. Craig PN,
    2. Nabenhauer FP,
    3. Williams PM,
    4. Macko E,
    5. Toner J
    : Tetrahydroisoquinolines. I. 1-Alkyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinolines. J Am Chem Soc 74: 1316-1317, 1952.
    OpenUrl
    1. Kawase M
    : Autoxidation of intermediary mesoionic 1,3-oxazolium-5-olates generated from cyclic N-acyl α-amino acids. Chem Pharm Bull 45: 1248-1253, 1997.
    OpenUrl
    1. Popp FD,
    2. Blount W,
    3. Soto A
    : Reissert compound studies: Generality of a new procedure. Chem Ind 1022, 1962.
    1. Brossi A
    : Mammalian alkaloids: conversions of tetrahydroisoquinoline-1-carboxylic acids derived from dopamine. Planta Medica 57: S93-S100, 1991.
    OpenUrlPubMed
    1. Gensler WJ,
    2. Bluhm AL
    : Cinnamic acids from tetrahydroisoquinolinecarboxylic acids. J Org Chem 21: 336-339, 1956.
    OpenUrl
  18. ↵
    1. Narasaka K,
    2. Kohno Y
    : Oxidative generation of N-acyliminium ions from N-1-(tributylstannyl)alkyl carboxamides and carbamates and their reactions with carbon nucleophiles. Bull Chem Soc Japan 66: 3456-3463, 1993.
    OpenUrl
  19. ↵
    1. Satoh R,
    2. Kishino K,
    3. Morshed SRM,
    4. Takayama F,
    5. Otsuki S,
    6. Suzuki F,
    7. Hashimoto K,
    8. Kikuchi H,
    9. Nishikawa H,
    10. Yasui T,
    11. Sakagami H
    : Changes in fluoride sensitivity during in vitro senescence of human normal oral cells. Anticancer Res 25: 2085-2090, 2005.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Sekine T,
    2. Takahashi J,
    3. Nishishiro M,
    4. Arai A,
    5. Wakabayashi H,
    6. Kurihara T,
    7. Kobayashi M,
    8. Hashimoto K,
    9. Kikuchi H,
    10. Katayama T,
    11. Kanda Y,
    12. Kunii S,
    13. Motohashi N,
    14. Sakagami H
    : Tumor-specificity and type of cell death induced by trihaloacetylazulenes in human tumor cell lines. Anticancer Res 27: 133-144, 2007.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Yanagisawa-Shiota F,
    2. Sakagami H,
    3. Kuribayashi N,
    4. Iida M,
    5. Sakagami T,
    6. Takeda M
    : Endonuclease activity and induction of DNA fragmentation in human myelogenous leukemic cell lines. Anticancer Res 15: 259-266, 1995.
    OpenUrlPubMed
  22. ↵
    1. Byfield MP,
    2. Murray JT,
    3. Backer JM
    : hVps34 is a nutrient-regulated lipid kinase required for activation of p70 S6 kinase. J Biol Chem 280: 33076-33082, 2005.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Saitoh T,
    2. Abe K,
    3. Ishikawa M,
    4. Nakatani M,
    5. Shimazu S,
    6. Satoh N,
    7. Yoneda F,
    8. Taguchi K,
    9. Horiguchi Y
    : Synthesis and in vitro cytotoxicity of 1,2,3,4-tetrahydroisoquinoline derivatives. Eur J Med Chem 41: 241-253, 2006.
    OpenUrlPubMed
  24. ↵
    1. Ishihara M,
    2. Hatano H,
    3. Kawase M,
    4. Sakagami H
    : Estimation of relationship between structure of 1,2,3,4-tetrahydroisoquinoline derivatives determined by a semiempirical molecular-orbital method and their cytotoxicity. Anticancer Res 29: in press, 2009.
  25. ↵
    1. Kang JH
    : Salsolinol, a tetrahydroisoquinoline catechol neurotoxin, induces human Cu,Zn-superoxide dismutase modification. J Biochem Mol Biol 40: 684-689, 2007.
    OpenUrlPubMed
  26. ↵
    1. Maruyama W,
    2. Naoi M,
    3. Kasamatsu T,
    4. Hashizume Y,
    5. Takahashi T,
    6. Kohda K,
    7. Dostert P
    : An endogenous dopaminergic neurotoxin, N-methyl-(R)-salsolinol, induces DNA damage in human dopaminergic neuroblastoma SH-SY5Y cells. J Neurochem 69: 322-329, 1997.
    OpenUrlPubMed
  27. ↵
    1. Deng Y,
    2. Luan Y,
    3. Qing H,
    4. Xie H,
    5. Lu J,
    6. Zhou J
    : The formation of catechol isoquinolines in PC12 cells exposed to manganese. Neurosci Lett 444: 122-126, 2008.
    OpenUrlPubMed
  28. ↵
    1. Kang GS,
    2. Wang XD,
    3. Mohler ML,
    4. Kirichendo OV,
    5. Patil R,
    6. Orr WE,
    7. Miller DD,
    8. Geisert EE
    : Effects, in an in vivo model system, of 1,2,3,4-tetrahydroisoquinoline on glioma. Anticancer Drugs 19: 859-870, 2008.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Anticancer Research
Vol. 29, Issue 8
August 2009
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Tumor-specific Cytotoxic Activity of 1,2,3,4-Tetrahydroisoquinoline Derivatives against Human Oral Squamous Cell Carcinoma Cell Lines
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
11 + 8 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Tumor-specific Cytotoxic Activity of 1,2,3,4-Tetrahydroisoquinoline Derivatives against Human Oral Squamous Cell Carcinoma Cell Lines
HAJIME HATANO, FUMIHIRO TAKEKAWA, KEN HASHIMOTO, MARIKO ISHIHARA, MASAMI KAWASE, CHU QING, WANG QIN-TAO, HIROSHI SAKAGAMI
Anticancer Research Aug 2009, 29 (8) 3079-3086;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Tumor-specific Cytotoxic Activity of 1,2,3,4-Tetrahydroisoquinoline Derivatives against Human Oral Squamous Cell Carcinoma Cell Lines
HAJIME HATANO, FUMIHIRO TAKEKAWA, KEN HASHIMOTO, MARIKO ISHIHARA, MASAMI KAWASE, CHU QING, WANG QIN-TAO, HIROSHI SAKAGAMI
Anticancer Research Aug 2009, 29 (8) 3079-3086;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgements
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • Quantitative Structure-Activity Relationship (QSAR) Analysis of Tumor-specificity of 1,2,3,4-Tetrahydroisoquinoline Derivatives
  • Estimation of Relationship Between Descriptors and Cytotoxicity of Newly Synthesized 1,2,3,4-Tetrahydroisoquinoline Derivatives
  • Google Scholar

More in this TOC Section

  • Insights From Matrix Metalloproteinase-2 Genotypes to Decipher the Genetic Architecture of Bladder Cancer Risk
  • Chemosensitizing Effects of Resveratrol Derivatives on p53-dependent Apoptosis Triggered by Cisplatin in Human Lung Cancer Cells
  • Advanced Reliability of Radiomic Features in Ex Vivo HypersightTM-CBCT Imaging by iCBCT-Acuros Reconstruction
Show more Experimental Studies
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire